JonesResearch analyst Soumit Roy initiated coverage of Coeptis Therapeutics with a Buy rating and $4 price target. Coeptis is a preclinical stage biotech company building a cell therapy platform with smart twists. the analyst tells investors in a research note. The firm sees a large opportunity for the company in multiple myeloma.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on COEP:
- Coeptis Rises on Key Assets Acquisition from Deverra
- Coeptis Therapeutics Signs Agreement to Acquire Allogeneic Immuno-Oncology NK Platform in Phase 1 Clinical Trials from Deverra Therapeutics
- Coeptis Therapeutics obtains exclusive rights to negotiate to acquire VyGen-Bio
- Coeptis Therapeutics Secures Exclusive Rights to Negotiate to Acquire Transformational Cell Therapy Platform to Enable Potent Combinatorial Immuno-Oncology Treatment Strategies
